Advertisement
Screener

Progyny, Inc. (PGNY) Graph

PGNY Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $350.51M; Revenue including tax (m); Cost of revenue $261.21M; Research and development $3.30M.
  • 2026-03-31: Revenue $328.50M; Revenue including tax (m); Cost of revenue $245.43M; Research and development $2.80M.
  • 2025-12-31: Revenue $318.40M; Revenue including tax (m); Cost of revenue $241.52M; Research and development $3.10M*.
  • 2025-09-30: Revenue $313.35M; Revenue including tax (m); Cost of revenue $240.51M; Research and development $2.60M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

PGNY revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.FertilityBenefit Services$230.21MPharmacyBenefit Services$120.30MRevenue$350.51MCost of revenue$261.21MGross profit$89.30MOperating expenses$49.30MOperating income$40.00MOther income, net$1.13MResearch & development$3.30MPre-tax income$41.14MIncome tax$13.08MNet income$28.05M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

PGNY revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$350.51MRevenue$350.51MCost of revenue$261.21MGross profit$89.30MOperating expenses$49.30MOperating income$40.00MOther income, net$1.13MResearch & development$3.30MPre-tax income$41.14MIncome tax$13.08MNet income$28.05M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$350.51M(m)$261.21M$3.30M$49.30M$13.09M$28.05M
2026-03-31$328.50M(m)$245.43M$2.80M$47.69M$12.65M$24.23M
2025-12-31$318.40M(m)$241.52M$3.10M*$61.66M$5.37M$12.48M
2025-09-30$313.35M(m)$240.51M$2.60M$51.31M$10.10M$13.86M
2025-06-30$332.87M(m)$253.90M$2.30M$54.62M$9.96M$17.11M
2025-03-31$324.04M(m)$248.24M$1.50M$51.63M$11.48M$15.06M
2024-12-31$298.43M(m)$235.00M(m)$47.65M$7.13M$10.53M
2024-09-30$286.63M$286.63M$227.38M(m)$46.79M$7.54M$10.42M
2024-06-30$304.09M$304.09M$235.81M(m)$47.59M$8.58M$16.48M
2024-03-31$278.08M$278.08M$215.67M(m)$43.88M$5.62M$16.90M
2023-12-31$269.94M(m)$213.05M(m)$43.09M$2.79M$13.47M
2023-09-30$280.89M$280.89M$218.27M(m)$44.44M$5.03M$15.90M
2023-06-30$279.37M$279.37M$218.73M(m)$45.46M$2.18M$14.99M
2023-03-31$258.39M$258.39M$199.75M(m)$43.63M-$1.35M$17.68M
2022-12-31$214.32M(m)$169.83M(m)$41.19M$733.00K$3.41M
2022-09-30$205.37M$205.37M$159.38M(m)$34.74M-$1.67M$13.21M
2022-06-30$195.00M$195.00M$151.12M(m)$35.05M$135.00K$8.77M
2022-03-31$172.22M$172.22M$139.27M(m)$33.01M-$5.11M$4.97M
2021-12-31$127.55M$127.55M$102.44M(m)$25.30M-$15.48M$15.08M
2021-09-30$122.28M$122.28M$93.79M(m)$19.43M-$7.68M$16.80M
2021-06-30$128.65M$128.65M$99.03M(m)$17.96M-$6.81M$18.73M
2021-03-31$122.13M$122.13M$93.23M(m)$17.10M-$3.37M$15.17M
2020-12-31(m)$100.30M$79.64M(m)$19.50M-$37.90M$39.07M
2020-09-30(m)$98.93M$78.09M(m)$16.01M(m)$4.82M
2020-06-30(m)$64.61M$52.65M(m)$13.03M(m)-$1.06M
2020-03-31(m)$81.02M$64.42M(m)$13.17M$116.00K$3.63M
2019-12-31(m)$65.12M$53.35M(m)$10.63M-$77.00K-$4.40M
2019-09-30(m)$61.20M$48.88M(m)$9.25M$25.00K-$8.21M
2019-06-30(m)$56.17M$44.72M(m)$9.10M$64.00K$1.52M
2019-03-31(m)$47.20M$37.23M(m)$6.85M$0.00$2.52M
2018-12-31(m)$29.19M$23.77M(m)$6.12M-$547.00K-$1.52M
2018-09-30(m)$27.80M$22.75M(m)$5.63M-$395.00K-$1.14M
2018-06-30(m)$26.16M$21.12M(m)$5.36M-$289.00K-$831.00K
2018-03-31(m)$22.26M$18.32M(m)$5.78M-$546.00K$4.15M

Revenue and expense 6 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$679.01M(m)$506.64M$6.10M$96.99M$25.74M$52.28M
2025-06-30$656.91M(m)$502.14M$3.80M$106.24M$21.44M$32.17M
2024-06-30$582.16M$582.16M$451.48M(m)$91.48M$14.20M$33.38M
2023-06-30(m)$537.77M$418.49M(m)$89.09M$829.00K$32.67M
2022-06-30(m)$367.22M$290.38M(m)$68.06M-$4.98M$13.74M
2021-06-30(m)$250.78M$192.26M(m)$35.06M-$10.18M$33.89M
2020-06-30(m)$145.63M$117.07M(m)$26.20M$116.00K$2.56M
2019-06-30(m)$103.36M$81.95M(m)$15.95M$64.00K$4.04M

Revenue and expense 9 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$970.26M(m)$742.65M$6.40M$157.55M$31.54M$46.03M
2024-09-30$868.79M$868.79M$678.86M(m)$138.26M$21.74M$43.80M
2023-09-30(m)$818.66M$636.75M(m)$133.52M$5.86M$48.57M
2022-09-30(m)$572.59M$449.76M(m)$102.80M-$6.65M$26.95M
2021-09-30(m)$373.07M$286.05M(m)$54.49M-$17.86M$50.69M
2020-09-30(m)$244.56M$195.16M(m)$42.21M$116.00K$7.39M
2019-09-30(m)$164.56M$130.82M(m)$25.20M$89.00K-$4.17M
2018-09-30(m)$76.21M$62.19M(m)$16.77M-$1.23M$2.19M

Revenue and expense 12 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$1.29B(m)$984.18M$9.50M$219.21M$36.91M$58.52M
2024-12-31$1.17B(m)$913.86M(m)$185.91M$28.87M$54.34M
2023-12-31$1.09B(m)$849.80M(m)$176.62M$8.65M$62.04M
2022-12-31$786.91M(m)$619.59M(m)$143.98M-$5.92M$30.36M
2021-12-31$500.62M$500.62M$388.49M(m)$79.80M-$33.33M$65.77M
2020-12-31$344.86M$344.86M$274.80M(m)$61.71M-$37.78M$46.46M
2019-12-31(m)$229.68M$184.18M(m)$35.83M$12.00K-$8.57M
2018-12-31(m)$105.40M$85.97M(m)$22.89M-$1.78M$661.00K
2017-12-31(m)$48.58M$41.18M(m)$18.41M-$3.00K-$12.45M

Similar stocks

Stock NameCountryMarket CapPE Ratio
agilon health, inc. (AGL)United States$1.272B-7.76
VIEMED HEALTHCARE, INC. (VMD)United States$0.336B29.92
Park Dental Partners, Inc. (PARK)United States$0.094B
BioRestorative Therapies, Inc. (BRTX)United States$0.064B
CRYO CELL INTERNATIONAL INC (CCEL)United States$0.033B-11.02
MANGOCEUTICALS, INC. (MGRX)United States$0.010B-0.43
Sotera Health Co (SHC)United States$5.271B30.96
DAVITA INC. (DVA)United States$11.147B16.80